Please login to the form below

Not currently logged in
Email:
Password:

Lundbeck reports profit fall

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m)

Danish drugs manufacturer Lundbeck has posted a 1.6 per cent fall in first-quarter net profit to DKK930m (€124.7m).

The company's revenue increased by 7 per cent to DKK4.1bn (€550m) in the first quarter, however, driven by a positive development of key products: antidepressant Cipralex (escitalopram), Alzheimer's treatment Ebixa (memantine) and Parkinson's treatment Azilect (rasagiline). Lundbeck said the products generated sales growth in the quarter, of 6 per cent, 12 per cent and 15 per cent respectively.

Ulf Wiinberg, chief executive, said: "It has been a good first quarter and several positive pipeline events have improved our long-term outlook."

The company still expects to make full-year sales of up to DKK15.8bn (€2.2bn). Earnings before interest and tax, depreciation and amortisation (EBITDA) is still expected to be up to DKK4.6bn (€616m).

5th May 2011

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Lucid Group Communications Limited

WE’RE ON A MISSION To enhance patients’ lives through communication that changes behaviour and improves patient health outcomes....

Latest intelligence

Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...
Ali Frederic Ben-Amor
Tackling a formidable foe
Ali Frederic Ben-Amor tells how Merck is taking the fight to multiple sclerosis...
Geoff
Cancer care – the power of new technologies
With patient numbers set to soar, how can we make a difference?...

Infographics